Repligen seeks six-month priority review of MRI pancreas agent
This article was originally published in Scrip
Executive Summary
Repligen has submitted a new drug application (NDA) to the US FDA for SecreFlo (RG1068), a synthetic version of human secretin, as an agent to detect pancreatic duct abnormalities in combination with MRI in patients with pancreatitis. The company is seeking a six-month priority review of the NDA.